Isoniazid is a mechanism-based inhibitor of cytochrome P450 1A2, 2A6, 2C19 and 3A4 isoforms in human liver microsomes
about
sameAs
Isoniazid metabolism and hepatotoxicityPharmacogenetic & pharmacokinetic biomarker for efavirenz based ARV and rifampicin based anti-TB drug induced liver injury in TB-HIV infected patientsComparative study of the effects of antituberculosis drugs and antiretroviral drugs on cytochrome P450 3A4 and P-glycoprotein.Isoniazid mediates the CYP2B6*6 genotype-dependent interaction between efavirenz and antituberculosis drug therapy through mechanism-based inactivation of CYP2A6.Cytochrome P450 family 1 inhibitors and structure-activity relationships.Isoniazid plus antiretroviral therapy to prevent tuberculosis: a randomised double-blind, placebo-controlled trialIsoniazid inhibits the heme-based reactivity of Mycobacterium tuberculosis truncated hemoglobin NStructure, function, regulation and polymorphism and the clinical significance of human cytochrome P450 1A2.Clinical outcomes and management of mechanism-based inhibition of cytochrome P450 3A4.An evaluation of potential mechanism-based inactivation of human drug metabolizing cytochromes P450 by monoamine oxidase inhibitors, including isoniazid.Drug interactions of clinical importance among the opioids, methadone and buprenorphine, and other frequently prescribed medications: a review.Drug bioactivation, covalent binding to target proteins and toxicity relevance.Efavirenz Pharmacokinetics and Pharmacodynamics in HIV-Infected Persons Receiving Rifapentine and Isoniazid for Tuberculosis PreventionRisk assessment of mechanism-based inactivation in drug-drug interactions.Role of metabolism in drug-induced idiosyncratic hepatotoxicity.Hydroxylation of 20-hydroxyvitamin D3 by human CYP3A4.In vitro approaches to investigate mechanism-based inactivation of CYP enzymes.CYP2C19 drug-drug and drug-gene interactions in ED patients.Antituberculosis drug-induced hepatotoxicity: concise up-to-date review.Pharmacologic Inhibition of Host Phosphodiesterase-4 Improves Isoniazid-Mediated Clearance of Mycobacterium tuberculosis.CYP2B6 (c.516G-->T) and CYP2A6 (*9B and/or *17) polymorphisms are independent predictors of efavirenz plasma concentrations in HIV-infected patients.Model-based evaluation of the pharmacokinetic differences between adults and children for lopinavir and ritonavir in combination with rifampicinEffects of rifampin-based antituberculosis therapy on plasma efavirenz concentrations in children vary by CYP2B6 genotype.Factors affecting interindividual differences in clozapine response: a review and case report.In vitro-to-in vivo predictions of drug-drug interactions involving multiple reversible inhibitors.Potential food-drug interactions in patients with rheumatoid arthritis.Mechanisms of isoniazid-induced idiosyncratic liver injury: emerging role of mitochondrial stress.Drug metabolism and drug interactions: potential application to antituberculosis drugs.Inhibitory Effects of Selected Antituberculosis Drugs on Common Human Hepatic Cytochrome P450 and UDP-glucuronosyltransferase Enzymes.CYP2B6 genotype, but not rifampicin-based anti-TB cotreatments, explains variability in long-term efavirenz plasma exposure.Is there a need to increase the dose of efavirenz during concomitant rifampicin-based antituberculosis therapy in sub-Saharan Africa? The HIV-TB pharmagene study.N-acetyltransferase 2 (NAT2) gene polymorphism as a predisposing factor for phenytoin intoxication in tuberculous meningitis or tuberculoma patients having seizures - A pilot study.Severe efavirenz-induced vacuolar axonopathy complicated by fatal aspiration pneumonia.More potent inhibition of human CYP2A6 than mouse CYP2A5 enzyme activities by derivatives of phenylethylamine and benzaldehyde.In vitro studies on the toxicity of isoniazid in different cell lines.Cocktail-substrate assay system for mechanism-based inhibition of CYP2C9, CYP2D6, and CYP3A using human liver microsomes at an early stage of drug development.A Novel Phenylchromane Derivative Increases the Rate of Glucose Uptake in L6 Myotubes and Augments Insulin Secretion from Pancreatic Beta-Cells by Activating AMPK.Pharmacokinetics of efavirenz in patients on antituberculosis treatment in high HIV and tuberculosis burden countries: a systematic review.Effect of Rifampicin and CYP2B6 Genotype on Long-Term Efavirenz Autoinduction and Plasma Exposure in HIV Patients With or Without Tuberculosis
P2860
Q28076859-6F4C3D7E-C5F6-42AF-BF94-1EF237F28999Q28478275-E1E27A16-38CE-4C6D-852B-B23FB69D0A18Q33797986-42B1E9DE-89D0-43C9-A5AB-FBF8915DA6F6Q33798516-BBE23112-81B3-4358-A382-EE126D6256ACQ34436975-A3133290-FF3F-47CA-B173-DBC0F311CA7FQ34519039-D54BEBCE-5E4C-4948-9E18-5877D08A6926Q34924586-A36AF577-18E3-41E2-A666-2908587C7DF5Q35015993-EC68C1DE-3D89-4D34-9672-D05B6A34D267Q35166632-CB5B0907-D226-4DCC-B900-F10AF2954C7CQ35827548-1D748547-9F67-4C9F-850F-BFDB0604C6DAQ35906594-204276E4-942F-499B-8C66-7C298BCA99EFQ36061821-3DB89A26-15EF-46EE-B3C4-B9837845C3EFQ36094233-90320C8E-7F33-48FA-9F7F-8CC11901D394Q36174265-B43B2480-9B62-4206-9BDB-53B0BF09B46FQ36179528-473B378A-F9BC-4EAF-98AD-5AF33327F7A2Q36767930-4B9020CD-943C-4E6E-ABA9-CFDABCF57D94Q36835799-4F2B0104-74F4-4F29-BD56-35E70A75DEC0Q36930041-119297DE-2AED-4B79-B385-8B6B0C07244BQ36998032-24ED450B-52A6-4DC7-8CBF-232432CF1B6EQ37014319-BFE77B2A-53A6-4140-90AE-06360EEC14B2Q37184431-D7FA8DEE-AEA4-416A-9B5E-97103E528045Q37369323-E0B7999A-AC4E-42C1-B0D4-21DC09C407C0Q37429325-30C946AA-CE0F-4BE5-A255-DED89435AD62Q37860249-71D1E377-6E2B-4F93-9E09-9BA57EBC9CFDQ37989979-0C5A2B7C-3C61-4BCC-AECA-B3123B09EEF4Q38115004-D6BB72BA-8EC3-4856-AEF1-1425923615C4Q38208324-4D865CED-C641-47B9-B5A5-C2DD354F4DBCQ38502286-FB4D7153-0388-415E-9F37-495DBA9F4064Q38701604-AC5979CA-FBC2-46DD-A153-413D26E6C72DQ38861140-E50BD4BC-6F74-46E0-A982-2A112A5A204CQ39039468-CAD36B1A-594E-4B83-9DEF-2F9816812E44Q41674917-A165F608-8888-4B47-8F59-F1D324C36E31Q42011164-BD0EA148-0339-462B-83E4-826EFB2282CCQ44440357-AC03B395-BB69-4FC4-A47A-AFFEFD624D3EQ44699895-51986947-75D8-4A54-9C03-7ED2E777A1BDQ45990604-C3598F9D-821E-4A40-A6B7-1BBB09E031D6Q47549959-80037BAA-0AE3-4B38-860D-7458CCB558E8Q52330065-CB727FBD-264A-4DA6-BC3F-208150A8F36FQ56829837-1C27F395-2B63-4ECE-9D2B-69E24A384D66
P2860
Isoniazid is a mechanism-based inhibitor of cytochrome P450 1A2, 2A6, 2C19 and 3A4 isoforms in human liver microsomes
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Isoniazid is a mechanism-based ...... orms in human liver microsomes
@ast
Isoniazid is a mechanism-based ...... orms in human liver microsomes
@en
Isoniazid is a mechanism-based ...... orms in human liver microsomes
@nl
type
label
Isoniazid is a mechanism-based ...... orms in human liver microsomes
@ast
Isoniazid is a mechanism-based ...... orms in human liver microsomes
@en
Isoniazid is a mechanism-based ...... orms in human liver microsomes
@nl
prefLabel
Isoniazid is a mechanism-based ...... orms in human liver microsomes
@ast
Isoniazid is a mechanism-based ...... orms in human liver microsomes
@en
Isoniazid is a mechanism-based ...... orms in human liver microsomes
@nl
P2093
P3181
P1476
Isoniazid is a mechanism-based ...... orms in human liver microsomes
@en
P2093
Janne T Backman
Jun-Sheng Wang
Pertti J Neuvonen
P2888
P304
P3181
P356
10.1007/S00228-001-0396-3
P407
P577
2002-01-01T00:00:00Z
P6179
1047576855